STANFORD UNIVERSITY

Fifty1 AI Labs successfully completed the REVIVE Adaptive Platform Trial, the largest and most rigorous Long COVID study to date, enrolling over 600 participants across multiple global sites.

Ashvattha Therapeutics will present data on two breakthrough nanomedicine radiotracers at the SNMMI Annual Meeting, demonstrating selective targeting capabilities in neuroinflammation and cancer.

Fujirebio has announced a strategic collaboration with Stanford Medicine to accelerate research and innovation in infectious disease testing using ultrasensitive immunoassays.

Stanford University researchers have developed a breakthrough milli-spinner thrombectomy technology that shrinks blood clots to just 5% of their original volume through a unique rotating mechanism.

The FDA has approved an expanded pediatric indication for the SONU Band, making it the first FDA-approved, drug-free solution for nasal congestion and allergies in children aged 12 years and older.

Continuity Biosciences has acquired Focal Medical, a North Carolina-based company developing site-specific chemotherapy using iontophoresis technology for pancreatic cancer treatment.

Matter Neuroscience has announced a collaboration with Stanford Medicine to conduct a controlled, multi-arm study enrolling at least 210 depressed patients using real-time 7T fMRI neurofeedback combined with the Matter protocol.

Stanford Medicine-led phase 3 trial demonstrates gene therapy skin grafts achieved 81% healing in epidermolysis bullosa wounds compared to 16% with standard care after 24 weeks.

FidoCure and Stanford researchers have published groundbreaking findings showing targeted therapies significantly improve survival rates in dogs with splenic hemangiosarcoma, the deadliest canine cancer.

• Valinor Discovery has launched an AI-powered platform that simulates patient responses to therapies before clinical testing, with initial applications in oncology and plans to release its first model within six months. • The company is generating proprietary longitudinal datasets that integrate multi-omics data with clinical assay results from the same patients, addressing the critical gap in high-quality clinical data for translatable biological models. • Strategic partnerships with Helmholtz Munich and Stanford Medicine will establish benchmarking standards for perturbation models and evaluate compounds targeting Alzheimer's disease, while a collaboration with Latch Bio provides no-code access to the platform.